Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis by Makela, Mika J. et al.
Clinical Therapeutics/Volume 40, Number 4, 2018Immunotherapy With the SQ Tree SLIT-tablet
in Adults and Adolescents With
Allergic RhinoconjunctivitisMika J. Ma¨kela¨, MD1; Pa¨r Gyllfors, MD, PhD2; Erkka Valovirta, MD3,4;
Maria A. Steffensen, MSc, PhD5; Pernille M. Grønager, BSc5; Johannes Savolainen, MD6;
and Lone Winther, MD7
1Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland; 2Asthma & Allergy
Department, St. Go¨ran’s Hospital, Sweden; 3Department of Pulmonary Diseases and Clinical Allergology,
University of Turku, Turku, Finland; 4Terveystalo Allergy Clinic, Helsinki, Finland; 5Global Research &
Development, ALK, Hørsholm, Denmark; 6Department of Pulmonary Diseases and Clinical Allergology,
University of Turku, Turku, Finland; and 7Department of Dermato-Allergology, Copenhagen University
Hospital, Copenhagen, DenmarkAccepted for publication February 16, 2018.
https://doi.org/10.1016/j.clinthera.2018.02.012
0149-2918/$ - see front matter
& 2018 Elsevier HS Journals, Inc. All rights reserved.ABSTRACT
Purpose: The SQ tree sublingual immunotherapy
(SLIT)-tablet containing allergen extracts with the
major allergen Bet v 1 from birch pollen is currently
being developed for the treatment of tree pollen–
induced allergic rhinitis/conjunctivitis with or without
asthma. The aim of this Phase II trial was to inves-
tigate the dose-related efficacy and safety of the SQ
tree SLIT-tablet.
Methods: This study was a randomized, parallel-
group, double-blind, placebo-controlled, multi-na-
tional trial conducted in Europe. A total of 637
participants were randomized equally to receive pla-
cebo or treatment with the SQ tree SLIT-tablet in
doses of 0.5, 1, 2, 4, 7, or 12 development units (DU).
Treatment was initiated ~16 weeks before onset of the
2013 birch pollen season (BPS) and was continued
throughout the BPS with a total duration of at least 6
months. During the BPS and tree pollen season (TPS),
subjects assessed rhinoconjunctivitis symptoms and
medication use on a daily basis in an electronic diary;
weekly assessments of rhinoconjunctivitis quality of
life were also made.
Findings: Analysis of the average daily symptom
score during the BPS and the TPS showed that the
difference between active treatment and placebo was
statistically significant for the 7 DU group (BPS, P ¼
0.02; TPS, P ¼ 0.03), with no clear dose–response
relationship. All doses of the SQ tree SLIT-tablet
induced changes from baseline in birch-specific IgE574and IgG4 that were statistically significant compared
with placebo at all time points assessed (P o 0.0001)
with a clear dose-response relationship for birch
specific IgG4. In general, the SQ tree SLIT-tablet was
well tolerated, with the majority of treatment-related
adverse events (≥95%) being mild or moderate in
severity. The most frequently reported treatment-
related adverse events were generally related to the
sublingual administration of the tablet (ie, they oc-
curred in the oral cavity).
Implications: The results from this trial suggest that
the SQ tree SLIT-tablet in doses up to 12 DU has
a tolerability profile suitable for at-home administra-
tion. The immunomodulatory changes indicate a
dose–response relationship, but clinical efficacy
parameters were inconclusive, probably due to low
pollen counts, emphasizing the importance of pollen
exposure for the outcome of a pollen allergy immu-
notherapy trial. EudraCT no: 2012-000031-59. (Clin
Ther. 2018;40:574–586) & 2018 Elsevier HS Jour-
nals, Inc. All rights reserved.
Key words: allergic rhinoconjunctivitis, birch pol-
len, clinical efficacy, immunology, sublingual immu-
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Allergic rhinitis has been identified as one of the main
reasons for visits to primary care clinics, and although
usually not regarded as a severe disease, it may affect
quality of life, social life, school learning performance,
and work productivity, especially if the patient’s
symptoms are moderate to severe. Furthermore, aller-
gic rhinitis is regarded as one of the major risk factors
for the development of asthma, and480% of patients
with asthma have rhinitis, whereas 10% to 40% of
people with rhinitis experience asthma.1,2
In Europe and North America, tree pollen–induced
allergic rhinitis/rhinoconjunctivitis is commonly
caused by allergens from the Fagales order, which
includes, among others, birch, alder, hazel, and oak.
They all belong to the birch homologous group and
are characterized by having Bet v 1 homologous
allergens with a high sequence identity, which leads
to extensive cross-reactivity. Thus, patients who are
sensitized to birch pollen often also experience symp-
toms in response to pollen from other members of the
birch homologous group, which prolongs the season
and extends the geographical area that can trigger
allergic reactions for these patients.3–5
A large number of pollen-allergic individuals also
develop allergic symptoms against certain foods such
as nuts and apples. The symptoms are manifested as a
condition called pollen food syndrome, and its occur-
rence typically involves presensitization to pollen
allergens from the Fagales order. The condition is
IgE-mediated and is caused by cross-reactive
allergens.6
Recommendations for the treatment of allergic
diseases are allergen avoidance, symptomatic medica-
tions such as antihistamines and corticosteroids, and
allergy immunotherapy (AIT).2 Avoidance of pollen
can be difficult to achieve in a normal daily life,
and allergy pharmacotherapy is widely used; however,
it does not offer causal treatment of the allergic
disease, and up to 44% of patients on optimal
pharmacotherapy report poor or only partial
symptom control.7
AIT is the only available treatment modality with
the potential to modify the natural course of the
allergic disease by induction of tolerance.2 The use
of pollen extract for AIT is well known, both in
subcutaneous formulations8–12 and as sublingual im-
munotherapy tablets or drops (SLIT-tablets/
drops).13,14 Birch pollen is recommended as aApril 2018representative allergen source for AIT targeting aller-
gies caused by pollen from the birch homologous
group. This recommendation is based on results from
in vitro inhibition studies in which birch pollen has
shown a high degree of inhibition of human IgE
binding to alder, hazel, and oak allergen
extracts.3,15,16
Although the exact mode of action of SLIT has not
been completely established, the downstream effects
include induction of IgG4 at the expense of IgE
production. IgG4 antibodies compete with IgE anti-
bodies for the binding of allergen and thus block the
cross-binding of immune cell–associated IgE.17,18 De-
creased allergen-specific IgE, as well as increased IgG1
and IgG4, have been shown to be hallmarks of
efficacious SLIT.17,19
A tree pollen SLIT-tablet containing allergen
extracts with the major allergen Bet v 1 from birch
pollen is currently being developed by ALK
(Hørsholm, Denmark) for the treatment of tree pol-
len–induced allergic rhinitis and/or conjunctivitis. The
aim of the present Phase II trial was to investigate the
dose-related efficacy and safety of the SQ tree SLIT-
tablet not only during the birch pollen season (BPS)
but also during other tree pollen seasons (TPSs) such
as hazel and alder.PATIENTS AND METHODS
Ethics
The trial was designed and conducted in accord-
ance with the principles of the Declaration of Helsinki
(1964, and its amendments and subsequent clarifica-
tions)20 and was conducted in compliance with the
principles of Good Clinical Practice.21 The trial was
approved by the local independent ethics committes/
institutional review board and/or the health authority
(as applicable) in each involved country before
initiation.
Trial Design
This randomized, parallel-group, double-blind,
placebo-controlled, multinational, multisite trial was
conducted in Europe. The trial included 65 sites in 7
countries (Denmark, Finland, Lithuania, the Nether-
lands, Norway, Poland, and Sweden). A total of 637
participants were randomized equally to receive pla-
cebo or treatment with the SQ tree SLIT-tablet in
doses of 0.5, 1, 2, 4, 7, or 12 development units (DU).575
N = 637
Placebo (n = 88)
0.5 Du (n = 93)
1 DU (n = 90)
2 DU (n = 89)
4 DU (n = 92)
7 DU (n = 88)
12 DU (n = 97)
Visits: Screening Randomization Off-season Pre-TPS Pre-BPS End of trial
Efficacy assessment
Figure 1. Trial overview. Participants were randomized equally to receive treatment with one of 6 doses of the
SQ tree SLIT-tablet or placebo. Treatment was initiated 16 weeks before onset of the 2013 birch
pollen season (BPS) and was continued throughout the BPS with a total duration of at least 6
months. DU ¼ development unit; TPS ¼ tree pollen season.
Clinical TherapeuticsTreatment was initiated ~16 weeks before onset of the
2013 BPS and was continued throughout the BPS,
with a total duration of at least 6 months. The trial
had first subject first visit on August 20, 2012, and last
subject last visit on July 5, 2013. The trial design,
including scheduled visits and treatment doses, is
illustrated in Figure 1.Trial Population
Written informed consent was obtained at the
screening visit before any other trial-related activities;
for subjects aged 15 to 17 years, subject consent and
parent/guardian consent was required, and for sub-
jects aged 12 to 14 years, subject assent and parent/
guardian consent was required. The trial population
consisted of adults and adolescents aged 12 to 65
years with a history of moderate to severe birch
pollen–induced allergic rhinoconjunctivitis (with or
without asthma), with symptoms despite having
received pharmacotherapy during the 2011 and
2012 BPSs. Subjects were also required to have had
an appropriate minimum level of birch pollen–induced
rhinoconjunctivitis symptoms during the previous BPS
(ie, 2012) defined as a daily symptom score (DSS) ≥8
on the worst day of the season. Symptoms during the576previous BPS were recorded by use of a retrospective
questionnaire. Further selection criteria included pres-
ence of one or more of 4 Allergic Rhinitis and its
Impact on Asthma quality of life items2 (sleep
disturbance; impairment of daily activities, leisure
and/or sport; impairment of school or work;
troublesome symptoms) caused by allergic
rhinoconjunctivitis during the previous BPS, positive
skin prick test (SPT) response (wheal diameter ≥3 mm
larger than the negative control) toward birch,
positive specific IgE to Bet v 1 (IgE class 2 or higher;
≥0.70 kU/L), no clinically relevant history of
perennial allergic rhinitis and/or asthma due to an
allergen to which the participant is regularly exposed
(eg, house dust mite, pets), no clinical history of
uncontrolled asthma within 3 months before
randomization, and no reduced lung function
(defined as FEV1 o70% in adults or FEV1 o80%
in adolescents), no treatment with immunotherapy
containing birch pollen allergen within the last 5 years
(or a cross-reacting allergen such as hazel or alder).Intervention Medication
Each participant was randomly assigned to receive
1 of 6 active doses of the SQ tree SLIT-tablet orVolume 40 Number 4
M.J. Ma¨kela¨ et al.placebo. The first dose was administered under med-
ical supervision lasting at least 60 minutes after tablet
intake. Participants were instructed to take 1 tablet
sublingually each day. The SQ tree SLIT-tablet is an
oral lyophilisate containing allergen extract derived
from birch pollen (Betula verrucosa), which was
standardized against an in-house reference based on
biological activity and defined in DUs. The interven-
tion medication was provided and manufactured by
the trial sponsor (ALK). The placebo tablet was also
an oral lyophilisate and was similar to the active
intervention medication with regard to appearance,
smell, taste, and packaging. Thus, the placebo tablets
were manufactured so that they could not be distin-
guished from the active intervention medication by the
subject or the investigator. Standardized pharmaco-
therapy for rhinoconjunctivitis symptoms (ie, deslor-
atadine tablets and olopatadine eye drops or
mometasone furoate nasal spray) was provided by
ALK to participants at randomization as predefined
open-label medication; it was to be used freely in
addition to the intervention medication to which the
participants had been randomized.
Randomization
Randomization was performed according to a
sponsor-generated allocation schedule by a trial-in-
dependent statistician. Randomization was stratified
according to sites by using block randomization. The
randomization list was divided into blocks of 7; that
is, for each 7 numbers, there was 1 set of each dose
including placebo. Allocation of randomization num-
bers to each site was initially done in blocks of 7
numbers. For resupplies, a complete block of 7
numbers was allocated to a site as for initial ship-
ments. If o7 numbers were allocated to a site, the
remaining numbers in that block were then kept free
for later allocation to the same site if needed. For
resupplies when complete 7-number blocks were no
longer available, randomization numbers from partly
used blocks were allocated. To the extent possible,
partly used blocks were only allocated to sites within
the same country. All subjects enrolled were identifi-
able throughout the trial by a 5-digit subject number
starting at 50001 allocated to the subjects at the
screening visit. When a subject was randomized to
treatment, a 4-digit randomization number starting at
1001 was also assigned. The investigator was to
always allocate the lowest randomization numberApril 2018available at the trial site to the subject. Randomization
codes were kept strictly confidential, accessible only to
authorized persons until the time of unblinding. At the
end of the trial, all randomization code envelopes
were collected, and reconciliation was performed
between any opened code envelopes and the code
breaks the sponsor had been notified about. The
randomization code was not broken for any subject
during the trial.
End Points and Assessments
Participants were instructed to complete symptom
and medication assessments and to record the results
in an electronic diary on a daily basis (in the evening
before bedtime) during the TPS. Investigators notified
subjects on when to start and stop entering data into
the electronic diary based on information on onset
and end of pollen seasons derived from the website of
European Pollen Information Ltd. Efficacy assess-
ments were based on all diary entries recorded during
the 2013 TPS (discussed later).
In total, 4 rhinitis symptoms (runny nose, blocked
nose, sneezing, and itchy nose) and 2 conjunctivitis
symptoms (gritty feeling/red/itchy eyes and watery
eyes) were measured on a scale from 0 to 3, where 0
corresponds to no symptoms and 3 to severe symp-
toms. For the medication score, subjects reported their
use of standardized pharmacotherapy.
The primary end point was the average rhinocon-
junctivitis DSS during the BPS (range, 0–18) for the
per-protocol (PP) analysis set (as discussed in the
Statistical Methods section). Secondary end points
included average daily (rhinoconjunctivitis) medica-
tion score (DMS) (range, 0–20) and average daily
total combined score (range, 0–38) calculated as the
sum of the average DSS and DMS for the full analysis
set (FAS) (as discussed in the Statistical Methods
section). Details of scoring scales are provided in
Supplemental Tables I and II in the online version at
https://doi.org/10.1016/j.clinthera.2018.02.012.
Disease-specific quality of life was assessed for adults
by using the Rhinoconjunctivitis Quality of Life
Questionnaire (RQLQ) with standardized activities;
this questionnaire was adapted from Juniper et al22
and was included in the electronic diary on a weekly
basis. Global evaluation of efficacy was performed at
the end-of-trial visit at which participants were asked to
compare rhinoconjunctivitis symptoms during the
2013 BPS versus the symptoms in the previous BPS577
Clinical Therapeutics(2012); subjects answering “better” or “much better”
were categorized as “improved,” and subjects answering
“much worse,” “worse,” or “the same” were categorized
as “not improved.”
Immunologic parameters were assessed to confirm
the diagnosis and evaluate the treatment-induced
specific immune response. Blood samples were drawn
for determination of allergen-specific IgE and IgG4 levels
at the screening visit, off-season visit, pre-TPS visit, pre-
BPS visit, and at the end-of-trial visit (Figure 1). The
samples were analyzed by the research department at
ALK using ImmunoCAP assays (Thermo Fisher
Scientific, Waltham, Massachusetts). IgE was measured
in kU/L and IgG4 in mgA/L.
Safety assessments included adverse events (AEs),
vital signs, physical examination, and clinical laboratory
investigations. Participants received a paper notebook to
complete every time they experienced an AE, and this
log served as the basis for AE assessment. AEs were
recorded from when the participants signed the informed
consent form and until the final follow-up; possible
relation to treatment was assessed by the investigator.Definition of TPS
Pollen counts were provided by European Pollen
Information Ltd. The BPS was defined with a start
date as the first day of 3 consecutive days with a birch
pollen count ≥30 grains/m3 and a stop date as the last
day in the last occurrence of 3 consecutive days with a
birch pollen count ≥30 grains/m3. The tree pollen
season was defined as the days included in any of the
hazel (defined by counts ≥5 grains/m3), alder (defined
by counts ≥10 grains/m3), or BPSs and was not
necessarily a continuous period in time.
Statistical Methods
Results were analyzed by using SAS version 8.02
(SAS Institute, Inc, Cary, North Carolina) and R.3.1.1
(R Foundation for Statistical Computing, Vienna,
Austria). All statistical analyses and CIs were 2-sided,
and a significance level of 5% was used. Group
comparisons regarding symptom and medication
scores were analyzed by using a linear mixed effect
model. RQLQ scores were analyzed in a repeated
measurement model. Pollen region was included as a
factor in the analysis model; that is, imbalances in
means between pollen stations were reflected in the
adjusted mean, resulting in an estimated mean of an578average person at an average pollen station. Baseline
comparability, immune responses, and safety assess-
ments were evaluated by summary statistics and shift
tables.
Two analysis sets were defined for this trial: the
FAS, defined as all randomized participants (637
participants), and the PP analysis set, defined as all
participants in the FAS with no major protocol
deviations that affect the primary efficacy end point
(453 participants). The PP set was defined by the
following 3 criteria: at least 70% treatment compli-
ance, at least 50% diary records in the BPS, and no
major protocol deviations. The PP set constituted the
primary dataset for the primary efficacy analysis.
Because this study was a Phase II trial, the stat-
istical analyses were mainly exploratory, and no
formal sample size calculation was performed. A
sample size of 85 was chosen for each dose group
because this number was expected to give a good
precision of the mean of the primary end point (the
average rhinoconjunctivitis DSS during the BPS). In
addition, this sample size allowed for the detection of
very common AEs (frequency 410%) with high
probability (499%) and of common AEs (41% to
≤10%) with a probability of455% within each dose
group.RESULTS
Subject Disposition and Baseline Characteristics
Table I presents an overview of subject disposition.
There were no major differences between groups in
terms of numbers of discontinuations and reasons for
discontinuation. However, there was a tendency
toward more discontinuations due to an AE in the
active treatment groups; 3% to 10 % of participants in
the active treatment groups discontinued due to an AE
versus 3% in the placebo group. A PP analysis set was
defined for each group, and the percentage of subjects
included in the PP analysis set was slightly lower for the
12 DU group compared with the other treatment
groups.
Table II presents the baseline characteristics. All
treatment groups were similar with regard to age, sex,
and years with birch pollen–induced rhinoconjunctivitis.
The majority (70%–81%) of participants experienced
pollen food syndrome as diagnosed according to the
questionnaire, whereas 25% to 35% had asthma. In
accordance with the inclusion criteria, all subjects hadVolume 40 Number 4
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M.J. Ma¨kela¨ et al.
April 2018moderate to severe birch pollen–induced rhino-
conjunctivitis and a positive SPT response toward
birch. Furthermore, 490% also had a positive SPT
response toward alder and hazel. All treatment groups
were similar in terms of rhinoconjunctivitis symptoms
experienced during the 2012 BPS, as well as the extent
and type of pharmacotherapy used during the 2012 BPS
(data not shown).
Pollen Exposure During the 2013 BPS
The trial was conducted during a pollen season that
was unusually low for birch as well as alder and hazel
pollen counts. Because some pollen regions (eg, Fin-
land) did not have birch pollen counts430 grains/m3,
and thus per definition did not have a BPS (represent-
ing 147 subjects; 30% of the FAS), a BPS with limits
of 10 grains/m3 was used for all BPS results presented
here. The average 2013 BPS (threshold, 30 grains/m3)
lasted 10 days, and the median birch pollen exposure
in 2013 was 114 grains/m3 per day for pollen regions
included in the trial. This situation is considered both
a short BPS and a low daily exposure level.
Rhinoconjunctivitis Symptoms and
Medication Scores
The primary efficacy end point was the average
DSS during the 2013 BPS, which was planned to be
analyzed by fitting appropriate dose–response curves
to the data from the BPS. However, as evident from
Figure 2A, which shows the mean rhinoconjunctivitis
DSS for the PP analysis set, the DSS did not display a
dose–response relationship. Therefore, none of the
planned models for fitting the data was appropriate
to execute, and a linear mixed effect model was used
instead.
As can be seen in Table III and Figure 2, analysis of
the average DSS during the BPS for the PP analysis set
found that the difference between active treatment and
placebo was significant for the 7 DU group (absolute
difference, 1.1; P ¼ 0.02; relative difference, 33%).
Analysis of the average DSS during the TPS for the PP
set also showed that the difference between active
treatment and placebo was statistically significant for
the 7 DU group (absolute difference, 0.8; P ¼ 0.03;
relative difference, 30%) with no clear dose–response
relationship. The difference between active treatment
and placebo in average DSS during the BPS and the
TPS was not statistically significant for the FAS (data
not shown).579
Table II. Demographic characteristics and allergy history.
Variable
0.5 DU
(n ¼ 93)
1 DU
(n ¼ 90)
2 DU
(n ¼ 89)
4 DU
(n ¼ 92)
7 DU
(n ¼ 88)
12 DU
(n ¼ 97)
Placebo
(n ¼ 88)
Age, y
Mean (SD) 34.7 (13.1) 35.4 (13.3) 36.2 (13.5) 35.5 (13.4) 36.6 (13.5) 37.5 (12.7) 37.6 (12.6)
Min–max 12–62 12–65 12–65 12–64 12–65 12–62 12–64
Sex, no. (%)
Female 44 (47) 45 (50) 48 (54) 46 (50) 38 (43) 48 (49) 40 (45)
Male 49 (53) 45 (50) 41 (46) 46 (50) 50 (57) 49 (51) 48 (55)
BMI, kg/m2
Mean (SD) 24.6 (3.7) 24.8 (4.0) 25.2 (4.8) 25.5 (4.8) 24.8 (4.1) 25.7 (4.9) 25.3 (4.6)
Min–max 18–38 17–36 18–45 15–39 18–38 16–49 16–45
Ethnic origin, no. (%)
White 91 (98) 89 (99) 85 (96) 87 (95) 84 (95) 94 (97) 85 (97)
Asian 2 (2) 1 (1) 1 (1) 2 (2) 2 (2) 1 (1) 1 (1)
African – – 2 (2) 2 (2) – 1 (1) –
Hispanic – – 1 (1) – 1 (1) – 1 (1)
Other – – – 1 (1) 1 (1) 1 (1) 1 (1)
Years with birch pollen–induced rhinoconjunctivitis, no. (%)
Mean (SD) 17.0 (11.7) 14.6 (10.3) 15.9 (10.8) 15.4 (10.5) 16.7 (11.2) 16.0 (11.4) 17.9 (12.5)
Min–max 1.6–50.0 0.7–42.3 1.0–42.0 0.6–49.4 1.0–52.0 1.5–43.0 1.1–50.0
Birch pollen–induced asthma, no. (%)
Yes 1 (1) 4 (4) 4 (4) 2 (2) 1 (1) 1 (1) 3 (3)
Unspecified asthma, no. (%)
Yes 29 (31) 25 (28) 28 (31) 27 (29) 21 (24) 34 (35) 23 (26)
Pollen food syndrome, no. (%)
Yes 65 (70) 70 (78) 66 (74) 69 (75) 71 (81) 70 (72) 67 (76)
BMI ¼ body mass index; DU ¼ development unit; Min–max ¼ minimum–maximum.
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Figure 2. Clinical efficacy. (A) Average rhinoconjunctivitis daily symptom score (DSS) during the 2013 birch
pollen season (BPS) for the per-protocol analysis set shown as adjusted means with 95% CIs. In
total, 4 rhinitis symptoms (runny nose, blocked nose, sneezing, and itchy nose) and 2 conjunctivitis
symptoms (gritty feeling/red/itchy eyes and watery eyes) were measured on a scale from 0 to 3,
where 0 corresponds to no symptoms and 3 to severe symptoms. (B) Global evaluation of efficacy for
the full analysis set. Subjects were asked to evaluate their symptoms during the 2013 BPS compared
with their symptoms during the 2012 BPS season. Subjects answering ”better” or ”much better” were
categorized as ”improved,” and subjects answering ”much worse,” ”worse,” or ”the same” were
categorized as ”not improved.” DU ¼ development unit. The asterisk indicates statistical significance.
M.J. Ma¨kela¨ et al.The DMS during the BPS and the TPS was
generally low for all treatment groups, and there
was no statistically significant difference between
active treatment and placebo for either the PP analysis
set or the FAS (Table III and data not shown).
As observed for the rhinoconjunctivitis DSS, the
total combined score for the 7 DU group during the
BPS and the TPS seemed to be lower than for the rest
of the groups, but there was no statistically significant
difference between active treatment and placebo for
either the PP analysis set or the FAS (data not shown).
Average overall RQLQ scores during both the BPS
and the TPS were ~1, implying that subjects’ quality of
life were on average “hardly troubled at all” by
rhinoconjunctivitis symptoms. Analysis of the average
RQLQ scores showed no statistically significant differ-
ence from placebo for the PP analysis set or for the
FAS (Table III and data not shown).
Global evaluation of efficacy revealed that the vast
majority of participants (480%) had improved com-
pared with the previous year, which was in accord-
ance with the 2013 pollen season being unusually low.
Although the primary efficacy assessment did not
reveal any dose–response relationship, there seemedApril 2018to be a trend toward a dose–response relationship for
the global evaluation, with more participants improv-
ing in the 12 DU group (94%) than in the placebo
group (80%) (Figure 2B). However, because the 95%
CIs were overlapping, the differences are not likely to
be statistically significant.
Immunology
Figure 3 illustrates the change from baseline in
birch-specific IgE and IgG4 from the screening visit
and until the end-of-trial visit for the FAS. All doses of
the SQ tree SLIT-tablet induced changes from baseline
in birch-specific IgE and IgG4 that were statistically
significant compared with placebo at all time points
assessed (P o 0.0001).
As evident from Figure 3A, IgE levels increased in
all active treatment groups from the screening visit
and until the off-season visit ~40 to 50 days after
initiation of treatment, after which the IgE levels
began to level off or even decrease for the 3 higher
dose groups (4, 7, and 12 DU). There was no clear
dose–response relationship for birch-specific IgE;
however, the 3 higher doses (4, 7, and 12 DU)
tended to induce a higher change from baseline than581
Table III. Analysis of daily symptom score (DSS), daily medication score (DMS), and Rhinoconjunctivitis
Quality of Life Questionnaire (RQLQ) for the longer birch pollen season.
Treatment No. Adjusted Means Difference From Placebo (95%) CI P
DSS (PP)
Placebo 57 3.4 – –
0.5 DU 70 3.1 0.3 (–0.7 to 1.3) 0.53
1 DU 67 3.8 –0.4 (–1.3 to 0.7) 0.51
2 DU 71 3.5 –0.02 (–1.1 to 1.0) 0.96
4 DU 65 3.4 0.1 (–0.9 to 1.0) 0.91
7 DU 61 2.3 1.1 (0.2 to 2.1) 0.02
12 DU 58 2.9 0.5 (–0.5 to 1.6) 0.30
DMS (PP)
Placebo 2 – –
0.5 DU 1.3 0.7 (–0.6 to 1.9) 0.29
1 DU 2.4 –0.5 (–1.9 to 0.9) 0.5
2 DU 1.7 0.2 (–1 to 1.5) 0.7
4 DU 1.5 0.4 (–0.8 to 1.7) 0.5
7 DU 1.4 0.5 (–0.7 to 1.8) 0.4
12 DU 2.3 –0.3 (–1.8 to 1.1) 0.66
RQLQ (PP)
Placebo 0.8 – –
0.5 DU 0.8 0.01 (–0.3 to 0.3) 0.9
1 DU 1 –0.1 (–0.5 to 0.2) 0.3
2 DU 0.9 –0.04 (–0.3 to 0.2) 0.8
4 DU 0.8 0.07 (–0.2 to 0.4) 0.7
7 DU 0.6 0.2 (–0.05 to 0.5) 0.1
12 DU 0.9 –0.06 (–0.4 to 0.3) 0.7
DU ¼ development unit; PP ¼ per protocol.
Clinical Therapeuticsthe lower doses (0.5, 1, and 2 DU). Birch-specific IgE
remained largely unchanged in the placebo group
throughout the trial at all time points assessed.
Birch-specific IgG4 increased throughout the trial in
all active treatment groups with a clear dose–response
relationship, whereas IgG4 remained constant at all
time points assessed in the placebo group (Figure 3B).
Thus, the SQ tree SLIT-tablet had a clear immune
modulatory effect with the higher doses (4, 7, and 12
DU) inducing higher changes from baseline in immu-
nologic parameters than the lower doses (0.5, 1, and
2 DU).
Safety
In general, the SQ tree SLIT-tablet had a favorable
safety profile, with the majority of treatment-related582AEs (≥95%) being of mild or moderate severity. A
total of 518 participants reported a total of 2333
treatment-related AEs, and there were more subjects
with treatment-related AEs in the active treatment
groups compared with placebo (Supplemental
Table III presents an overview of AEs in the online
version at https://doi.org/10.1016/j.clinthera.2018.02.
012). The number of reported treatment-related AEs
followed a dose–response trend with more treatment-
related AEs being reported by participants in the
higher dose groups. Severe treatment-related AEs
were only reported by participants in the active
treatment groups (68 AEs in 36 participants), but
there was no clear dose–response relationship. The
majority of severe treatment-related AEs were related
to the sublingual administration of the tablet (ie, theVolume 40 Number 4
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Figure 3. Immunology. Change from baseline in birch-specific (A) IgE and (B) IgG4 from the screening visit
and until the end-of-trial visit for the full analysis set. The graphic shows means with SEM. All doses
of the SQ tree sublingual immunotherapy tablet induced changes from baseline in birch-specific IgE
and IgG4 that were statistically significant compared with placebo at all time points assessed. DU ¼
development unit.
M.J. Ma¨kela¨ et al.AEs occurred in the oral cavity) or to the allergic
disease, and they were not clustered within 1 particular
system organ class or preferred term (see Supplemental
Table IV in the online version at https://doi.org/
10.1016/j.clinthera.2018.02.012). Thirty severe120
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Clinical Therapeuticsa full recovery. One treatment-related severe event of
hypersensitivity was reported in the 4 DU group, but
the event did not lead to discontinuation, and the
subject made a full recovery. One treatment-related
serious AE concerning severe asthma was reported in
the 1 DU group. The participant was treated with
antihistamine, corticosteroid, adrenaline, and oxygen,
and the event led to discontinuation from the trial
after 8 days of treatment. The subject made a full
recovery.
Thirty-one participants in the active treatment
groups discontinued due to 62 treatment-related AEs
that were not dependent on dose. Three participants
in the placebo group discontinued due to 6 treatment-
related AEs.
The most frequently reported treatment-related AEs
(occurring in 410% of subjects in any treatment
group) are illustrated in Figure 4. There was no clear
dose–response relationship for any of the most
frequently reported AEs, but these were reported by
more participants (81% [n ¼ 444]) in the active
treatment groups compared with placebo (36% [n ¼
32]). The majority of the most frequently reported
treatment-related AEs were related to the sublingual
administration of the tablet (ie, they occurred in the
oral cavity). The 4 most frequently reported related
AEs were oral pruritus, throat irritation, ear pruritus,
and mouth edema; oral pruritus was reported most
frequently. The majority of the most frequently
occurring treatment-related AEs had onset within a
few days after treatment initiation, resolved within ≤2
months, and were mild or moderate in severity (≥97%
for any treatment group).
No treatment-related changes were observed with
regard to clinical laboratory assessments, physical
examinations, or vital signs, and there were no major
differences between treatment groups in any of the
parameters assessed.DISCUSSION
This Phase II trial was designed to investigate the
dose–response of the SQ tree SLIT-tablet with respect
to clinical end points, immunology, and safety. Six
different doses were included to give a thorough
knowledge of the dose-related efficacy of the SQ tree
SLIT-tablet and provide a basis for selecting the
proper dose for the treatment of individuals allergic
to tree pollen. The trial did not report a dose–response584relationship for the primary end point (the rhinocon-
junctivitis DSS) during the BPS, nor for the secondary
end points DSS during the TPS and DMS and total
combined score during the BPS and TPS.
The TPS in 2013 was very weak, with median
pollen counts reported from pollen stations located
near trial sites of 114 grains/m3 per day. The accu-
mulated pollen counts reported from pollen stations
located near finish sites, which included 150 of the
637 trial participants, were 331 to 895 pollen grains/
m3 in 2013. For reference, an analysis of airborne
birch pollen in Finland from 1974 to 2004 reported
accumulated pollen counts of 590 to 38,713 grains/
m3,23 underlining the fact that 2013 was a highly
unusual year in terms of birch pollen. An earlier study
showed that clinical efficacy of pollen AIT is closely
associated with the level of pollen exposure,24 and this
finding is in accordance with the results from our
study. Generally, the clinical efficacy of SLIT has been
shown to improve with increasing allergen dose,25,26
and thus, it is most likely that the 12 DU dose would
show the same clinical efficacy as the 7 DU dose in a
setting with higher pollen exposure; another dose-
finding study is necessary to establish the optimal
dose for clinical efficacy of the SQ tree SLIT-tablet.
Dose-finding studies can also be performed by using
allergen exposure chambers as stated in the European
Medicines Agency guideline on the clinical develop-
ment of products for specific immunotherapy for the
treatment of allergic diseases. This approach is in-
dependent of pollen counts and is a good alternative
to field trials that are highly dependent on pollen
counts, which may vary greatly from year to year.
Dose findings from Phase II trials performed in
allergen exposure chambers should then be confirmed
during a larger Phase III field trial.
In contrast to clinical efficacy, immunologic assess-
ments are independent of pollen exposure and may
thus provide a basis for evaluation of the dose-related
efficacy of the SQ tree SLIT-tablet. Currently, the
exact correlation between immunologic factors such
as IgE and IgG4 and clinical efficacy as defined by
reduced rhinoconjunctivitis symptoms and medica-
tions use is not known; however, immunologic assess-
ments may provide an indicator for the immunologic
response to treatment.27 This trial included 2
immunologic end points: change from baseline in
IgE and IgG4. Both immunologic parameters showed
a dose–response trend, with doses of 4 DU or higherVolume 40 Number 4
M.J. Ma¨kela¨ et al.inducing greater changes from baseline compared with
the lower doses of 0.5 to 2 DU; however, while
serum levels of IgG4 increased throughout the trial,
serum levels of IgE began to level off after 2 months
of treatment. A previous study on the SQ grass
SLIT-tablet has shown that increased allergen-
specific serum IgG1 and IgG4, and decreased serum
IgE, may be indicators of clinical efficacy.19 Thus,
the immunomodulatory effects observed in this trial
suggest that doses of 4 DU or higher may provide the
best treatment effect.
The safety end points are also considered pollen
independent, as the majority of AEs reported with
SLIT-tablets are reported at treatment initiation and
therefore outside the pollen season. Generally, the SQ
tree SLIT-tablet was well tolerated, with 495% of
treatment-related AEs being of mild or moderate
severity. The number of treatment-related AEs fol-
lowed a dose–response trend, but number of severe
related AEs did not. Furthermore, the proportion of
subjects who discontinued due to treatment-related
AEs was similar between active treatment groups,
and all doses were therefore considered tolerable and
safe for at-home administration, provided that the
first tablet is administered under medical supervision.
The most frequently reported related AEs were local
reactions related to the sublingual administration of
the tablet such as oral pruritus, throat irritation, ear
pruritus, and mouth edema. Onset was typically
within a few days of treatment initiation, and reso-
lution was within 2 months. The safety profile of the
SQ tree SLIT-tablet trial reported here confirms
previous results from a Phase I trial with the SQ tree
SLIT-tablet.28 Furthermore, clinical trials conducted
with the corresponding SQ grass SLIT-tablet and the
SQ house dust mite SLIT-tablet showed a similar
safety profile, with the majority of related AEs being
local transient AEs, primarily mild or moderate in
severity affecting the mouth and throat.29,30CONCLUSIONS
The results from this trial suggest that the SQ tree
SLIT-tablet in doses up to 12 DU has a tolerability
profile suitable for at-home administration. The immuno-
modulatory changes indicated a dose-response relation-
ship, but clinical efficacy parameters were inconclusive,
probably due to low pollen counts, emphasizing the
importance of pollen exposure for the outcome of aApril 2018pollen AIT trial. Another Phase II dose-finding trial
assessing symptoms during controlled allergen expo-
sure in an allergen exposure chamber was initiated
after completion of the TT-02 trial.ACKNOWLEDGMENTS
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Supplementary Tables I–IV.Supplementary Table I. Sympton scoring scale.
Rhinoconjunctivitis symptoms Daily score
Rhinitis symptoms
Runny nose 0-3
Blocked nose 0-3
Sneezing 0-3
Itchy nose 0-3
Rhinitis DSS 0-12
Conjunctivitis symptoms
Gritty feeling/red/itchy eyes 0-3
Watery eyes 0-3
Conjunctivitis DSS 0-6
Rhinoconjunctivitis DSS 0-18Supplementary Table II. Pharmacotherapy scoring scale.
Rhinoconjunctivitis pharmacotherapy Score/dose unit Daily score
Desloratadine tablets (5 mg/tablet) 6 0-6
Olopatine eye drops (1 mg/ml) 1.5 0-6
Mometasone furoate nasal spray (50 pg/puff) 1 0-8
Rhinoconjunctivitis DMS 0-20
April 2018 586.e1
Supplementary Table III. Overview of AEs.
0.5 DU 1 DU 2 DU 4 DU 7 DU 12 DU Placebo
N ¼93 N ¼90 N ¼89 N ¼92 N ¼88 N ¼97 N ¼88
n
(%n)
e
(%e)
n
(%n)
e
(%e)
n
(%n)
e
(%e)
n
(%n)
e
(%e)
n
(%n)
e
(%e)
n
(%n)
e
(%e)
n
(%n)
e
(%e)
All AEs 85 (91) 442 (100) 78 (37) 397 (100) S3 (93) 539 (100) 86 (93) 572 (100) 82 (93) 513 (100) 89 (92) 652 (100) 71 (31) 305 (100)
Causality
Unlikely 64 (69) 172 (39) 50 (56) 133 (34) 58 (65) 166 (31) 55 (60) 154 (27) 43 (49) 120 (23) 58 (60) 175 (27) 57 (65) 167 (55)
Possible 74 (80) 270 (61) 74 (82) 264 (64) 75 (84) 373 (69) 83 (90) 418 (73) 79 (90) 393 (77) 85 (88) 477 (73) 48 (55) 138 (45)
Severity
Mild 80 (86) 304 (89) 73 (81) 277 (70) 78 (88) 422 (78) 80 (87) 425 (74) 77 (88) 346 (67) 80 (82) 447 (69) 59 (67) 207 (68)
Moderate 43 (46) 123 (28) 42 (47) 104 (26) 40 (45) 104 (19) 48 (52) 126 (22) 45 (51) 145 (28) 55 (57) 177 (27) 38 (43) 86 (28)
Severe 8 (9) 15 (3) 10 (11) 16 (4) 8 (9) 12 (2) 11 (12) 21 (4) 11 (13) 22 (4) 15 (15) 28 (4) 6 (7) 12 (4)
Unknown - - - - 1 (1) 1 (o1) - - - - - - - -
Seriousness
Serious - - 1 (1) 1 (1) 2 (2) 2 (o1) 1 (1) 1 (o1) - - 5 (5) 5 (o1) - -
Non-serious 85 (91) 442 (100) 78 (47) 396 (499) 83 (93) 537 (499) 86 (93) 571 (499) 82 (93) 513 (100) 89 (92) 647 (499) 71 (81) 305 (100)
Outcome
Recovered 85 (91%) 420 (95%) 78 (87%) 385 (97%) 83 (93%) 523 (97%) 85 (S2%) 547 (96%) 82 (93%) 497 (97%) 89 (92%) 627 (96%) 69 (78%) 288 (94%)
Recovered with sequelae 1 (1%) 1 (o1%)
Not recovered 13 (14%) 18 (4%) 10 (11%) 11 (3%) 11 (12%) 15 (3%) 13 (14%) 21 (4%) 11 (13%) 13 (3%) 13 (13%) 23 (4%) 7 (8%) 10 (3%)
Unknown 4 (4%) 4 (o1%) 1 (1%) 1 (o1%) 1 (1%) 1 (o1%) 2 (2%) 4 (o1%) 3 (3%) 3 (o1%) 1 (1%) 1 (o1%) 3 (3%) 7 (2%)
AES leading to
discontinuation
7 (8) 14 (3) 7 (8) 14 (4) 3 (3) 4 (o1) 4 (4) 15 (3) 9 (10) 13 (3) 7 (7) 16 (2) 3 (3) 6 (2)
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Supplementary Table IV. Severe IMP-related AEs.
0.5 DU 1 DU 2 DU 4 DU 7 DU 12 DU
SOC N ¼93 N ¼90 N ¼89 N ¼92 N ¼88 N ¼97
PT n (%n) e n (%n) e n (%n) e n(o%n) e n (%n) e n (%n) e
All events 6 (6%) 10 7 (8%) 11 2 (2%) 2 2 (2%) 12 9 (10%) 18 5 (5%) 15
Ear and labyrinth disorders
Ear pruritus 1 (1%) 1
Vertigo 1 (1%) 1
Eye disorders
Conjunctivitis allergic 1 (1%) 1
Eye pruritus 1 (1%) 1
Gastrointestinal disorders
Abdominal pain 1 (1%) 1
Dyspepsia 1 (1%) 1
Lip oedema 1 (1%) 1
Lip swelling 1 (1%) 1
Mouth ulceration 1 (1%) 1 1 (1%) 1
Nausea 1 (1%) 1
Edema mouth 2 (2%) 2 1 (1%) 1 2 (2%) 2 1 (1%) 1
Oral pain 1 (1%) 1 1 (1%) 3
Oral pruritus 1 (1%) 1 2 (2%) 2 2 (2%) 3 2 (2%) 2 2 (2%) 3
Palatal edema 1 (1%) 1
Swollen tongue 1 (1%) 1 2 (2%) 2
Tongue blistering 1 (1%) 1
Tongue pruritus 1 (1%) 1
General disorders and administration site conditions
Chest discomfort 1 (1%) 1
Malaise 1 (1%) 1
Sensation of foreign 1 (1%) 1
body
Immune system disorders
Hypersensitivity 1 (1%) 1
Oral allergy syndrome 1 (1%) 1
Seasonal allergy 1 (1%) 1
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Supplementary Table IV. (continued).
0.5 DU 1 DU 2 DU 4 DU 7 DU 12 DU
SOC N ¼93 N ¼90 N ¼89 N ¼92 N ¼88 N ¼97
PT n (%n) e n (%n) e n (%n) e n(o%n) e n (%n) e n (%n) e
Infections and infestations
Nasopharyngitis 1 (1%) 1
Nervous system disorders
Aphonia 1 (1%) 1
Headache 1 (1%) 1
Respiratory, thoracic and mediastinal disorders
Asthma 1 (1%) 1
Cough 1 (1%) 1 1 (1%) 1 1 (1%) 1 2 (2%) 2
Dyspnea 2 (2%) 2
Nasal congestion 1 (1%) 1
Pharyngeal edema 1 (1%) 1 2 (2%) 2
Respiratory stress 1 (1%) 1
Rhinorrhea 1 (1%) 1
Sneezing 1 (1%) 1
Throat irritation 2 (2%) 2
Throat tightness 1 (1%) 1 1 (1%) 1
Skin and subcutaneous tissue disorders
Pruritus 1 (1%) 1
Urticaria 1 (1%) 1
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